Clinical trials: Severe Pneumonia
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)
This is a Phase IIb, randomized, controlled, observer-blinded, clinical trial to evaluate safety and immunogenicity of COVID-19 Vaccine HIPRA in adult healthy volunteers in Vietnam
- Trial name
- NCT05142514
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- Vietnam
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
Covid19
Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center
Study to compare the efficacy and safety of colchicine and glucocorticoids compared with the standard of treatment for moderate/severe COVID-19 in a fragile and vulnerable population, admitted to a geriatric hospital unit or in a…
- Trial name
- NCT04492358
- Testing
- Colchicine, Prednisone tablet, standard of care
- Where
- 3 sites in Spain
- Volunteers
- 54 people
- Sponsor
- Maria Joyera Rodríguez
SARS-CoV-2
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
The primary purpose of this study is to evaluate the efficacy and safety of secutrelvir in symptomatic nonhospitalized adult and adolescent participants with COVID-19 who are at high risk for progression to severe disease.
- Trial name
- NCT07743580
- Testing
- Secutrelvir
- Where
- 51 sites in United States, Bulgaria and 1 more
- Volunteers
- 2,000 people
- Sponsor
- Shionogi
COVID-19
Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection
Flonoltinib Maleate (FM) is a triple-target inhibitor of JAK2, FLT3, and CDK6. It inhibited JAK2 with an IC50 of 0.8 nM, whereas its IC50 values against JAK1, JAK3, and TYK2 were 690 nM, 557 nM, and 65 nM, respectively…
- Trial name
- NCT05713279
- Testing
- SOC
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
SARS Pneumonia
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis
In a Phase 2 Simon's Optimal Two-Stages Design intravenous tocilizumab will be administered as single 8mg/Kg dose in patients affected by severe multifocal interstitial pneumonia correlated to SARS-CoV2 infection.
- Trial name
- NCT04315480
- Testing
- Tocilizumab
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Università Politecnica delle Marche
Rheumatic Diseases, SARS-CoV Infection
Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination
To date, studies on SARS-CoV2and vaccines have been mostly from the general population not exposed to immunosuppressants. The efficacy and safety of COVID-19 vaccines need to be evaluated in these populations.
- Conditions
- Rheumatic Diseases, SARS-CoV Infection, COVID-19
- Trial name
- COVID-RIC3 (NCT04832022)
- Testing
- Biological samples
- Where
- 13 sites in France
- Volunteers
- 397 people
- Sponsor
- University Hospital, Montpellier
H1N1 Pneumonia, Hypoxemia
Rapamune Improves Outcomes of Severe H1N1 Pneumonia
Severe H1N1 pneumonia with acute respiratory failure shows hyperactive immune cells infiltration of lung. Rapamune, a mTOR inhibitor, modulates the immune response by blocking activation of T- and B-cells.
- Trial name
- NCT01620307
- Testing
- Sirolimus (Rapamune 2mg/day, Pfizer)
- Volunteers
- 38 people
- Sponsor
- Chang Gung Memorial Hospital
SARS-CoV2 Infection, Rare Diseases
Identification of Factors Associated With the Occurrence of Severe Forms of COVID-19 Infection in Patients With Inflammatory Rheumatism or Autoimmune Diseases
Factors associated with severe forms of COVID-19 infection in patients with inflammatory rheumatic diseases (IRD) or Autoimmune Diseases (AID) are unknown.
- Conditions
- SARS-CoV2 Infection, Rare Diseases, Chronic Inflammatory Rheumatism, Autoimmune Diseases
- Trial name
- CovAID (NCT05026892)
- Testing
- no intervention
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Utilizing the Crosstalk Among Aerosolized Phenformin , Methylene Blue, Photodynamic Therapy , Zinc and Potassium for Treating Severe COVID-19 Infection and Its Inflammatory Complication
Utilizing the crosstalk among aerosolized phenformin, methylene blue, photodynamic therapy , zinc and potassium for treating severe COVID-19 infection and its inflammatory complication Amr Ahmed(1), Mahmoud Elkazzaz(2), Tamer…
- Trial name
- NCT05003492
- Testing
- Combination therapy plus Standard therapy, Photodynamic therapy, Standard therapy
- Where
- Saudi Arabia
- Volunteers
- 2 people
- Sponsor
- Amr kamel khalil Ahmed
Covid19, SARS-CoV Infection
The DAWN Antivirals Trial for Ambulatory COVID-19 Patients
This is a prospective, placebo controlled, individually randomized controlled phase III trial in Primary Care, assessing the efficacy of antivirals, i.e. camostat and molnupiravir, in accelerating recovery in Covid-19 patients.
- Trial name
- DAWN (NCT04730206)
- Testing
- Camostat, Molnupiravir
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- KU Leuven
COVID-19
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an injection into a vein.
- Trial name
- BLAZE-5 (NCT04701658)
- Testing
- Bamlanivimab
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Covid19
Respiratory Muscle Function, Dyspnea, Exercise Capacity and Quality of Life in Severe COVID19 Patients
Further knowledge regarding sequelae in severe COVID-19 patients who have required ICU admission for invasive mechanical ventilation is still needed.
- Trial name
- NCT04853940
- Testing
- Data collection and clinical testing of subjects
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Healthy Volunteers
A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
The purpose of this study is to learn about the safety and tolerability of different doses of REGN17092 administered with a needle either under the skin (called "subcutaneous") or into a vein (called an "infusion") in healthy…
- Trial name
- NCT05923424
- Testing
- REGN17092
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Post-intensive Care Syndrome, COVID-19
Clinical and Functional Characteristics of Patients Admitted for Severe COVID-19 Pneumonia
This research protocol aims to evaluate the impact of severe COVID-19 pneumonia requiring invasive mechanical ventilation (IMV) on health-related quality of life (HRQoL), functional capacity, muscle strength, and nutritional…
- Trial name
- EQOL-COVID (NCT06727474)
- Testing
- Health-Related Quality of Life (HRQoL) with EQ-5D-3L
- Where
- Argentina
- Volunteers
- 51 people
- Sponsor
- Hospital Nacional Profesor Alejandro Posadas
Sepsis, ARDS
Early Severe Illness TrAnslational BioLogy InformaticS in Humans
Advanced stages of the response to life-threatening infection, severe trauma, or other physiological insults often lead to exhaustion of the homeostatic mechanisms that sustain normal blood pressure and oxygenation.
- Conditions
- Sepsis, ARDS, Critical Illness, Neurocognitive Dysfunction
- Trial name
- ESTABLISH (NCT05591924)
- Testing
- Phelebotomy, Broncheoalveolar Lavage, Tracheal Aspirate
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Ventilator Associated Pneumonia, Infections
Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial
Probiotics are commercially available live bacteria thought to have health benefits when ingested. A literature review of probiotic studies in the intensive care unit (ICU) found that in patients who receive probiotics, there is…
- Conditions
- Ventilator Associated Pneumonia, Infections, C-Difficile, Antibiotic-associated Diarrhea
- Trial name
- PROSPECT (NCT02462590)
- Testing
- L. rhamnosus GG - Probiotic
- Where
- 44 sites in United States, Canada and 1 more
- Volunteers
- 2,650 people
- Sponsor
- McMaster University
Covid19
Rehabilitation in Intensive Care Unit
It was aimed to evaluate the respiratory functions of patients who were hospitalized in intensive care due to Covid-19 and given respiratory rehabilitation, in-bed positioning, and early mobilization, and the time of leaving the…
- Trial name
- NCT04713540
- Where
- Turkey (Türkiye)
- Volunteers
- 58 people
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Severe Covid-19
Safety and Efficacy of Medications COVID-19
We performed a quasi-experimental open-label pragmatic study alternating standard of care (SOC) and oral bedtime melatonin (OBM) at different high doses over 4 consecutive time periods enrolling all consecutive RT-PCR SARS-CoV-2…
- Trial name
- NCT05596617
- Testing
- Oral bedtime melatonin
- Where
- Spain
- Volunteers
- 335 people
- Sponsor
- Hospital San Carlos, Madrid
CoronaVirus Induced Disease-2019 (COVID-19)
Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- iNSPIRE (NCT04375397)
- Testing
- Ibrutinib
- Where
- 9 sites in United States
- Volunteers
- 46 people
- Sponsor
- AbbVie
COVID-19 Infection
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19
This study is to explore the safety and efficacy of using UCMSC01 in patients with COVID-19 infection via IV stem cell administration.
- Trial name
- UMSC01 (NCT05501418)
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Controlled normal saline
- Where
- Taiwan
- Volunteers
- 75 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.